Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

NCT00511706 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Age-Related Maculopathy

Interventions

DRUG: dexamethasone
BIOLOGICAL: ranibizumab
OTHER: sham

Sponsor

Allergan